35691-16-8

Basic information

• Product Name: (2-Chloroquinazolin-4-yl)-dimethylamine
• Synonyms: (2-Chloroquinazolin-4-yl)-dimethylamine;2-Chloro-N,N-diMethylquinazolin-4-aMine
• CAS NO: 35691-16-8
• Molecular Formula: C₁₀H₁₀ClN₃
• Molecular Weight: 207.6595
• Mol File: 35691-16-8.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 276.165°C at 760 mmHg
• Flash Point: 120.82°C
• Appearance: /
• Density: 1.298g/cm³
• Vapor Pressure: 0.005mmHg at 25°C
• Refractive Index: 1.666
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (2-Chloroquinazolin-4-yl)-dimethylamine(CAS DataBase Reference)
• NIST Chemistry Reference: (2-Chloroquinazolin-4-yl)-dimethylamine(35691-16-8)
• EPA Substance Registry System: (2-Chloroquinazolin-4-yl)-dimethylamine(35691-16-8)

Safety Data

• Hazardous Substances Data: 35691-16-8(Hazardous Substances Data)

Usage

General Description

(2-Chloroquinazolin-4-yl)-dimethylamine is a chemical compound with the molecular formula C10H11N3Cl. It is a quinazolinamine derivative with a chloro substituent at the 2 position. (2-Chloroquinazolin-4-yl)-dimethylamine is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is also used as a building block in organic synthesis for the preparation of various bioactive compounds. The chemical structure of (2-Chloroquinazolin-4-yl)-dimethylamine makes it a valuable tool in medicinal chemistry for the development of novel therapeutic agents. Additionally, it can be used as a reagent in chemical reactions to introduce the (2-chloroquinazolin-4-yl) group into organic molecules, making it a versatile and important compound in the field of organic and medicinal chemistry.

InChI:InChI=1/C10H10ClN3/c1-14(2)9-7-5-3-4-6-8(7)12-10(11)13-9/h3-6H,1-2H3

Upstream product

• 66433-07-6 2-chloro-4-methylthioquinazoline 
• 124-40-3 dimethyl amine 
• 607-68-1 2,4-dichloroquinazoline 
• 86-96-4 1,2,3,4-tetrahydro-quinazoline-2,4-dione 
• 118-92-3 anthranilic acid 

Downstream Products

• 757981-34-3 C₁₇H₁₇N₃O 
• 1215357-72-4 2-{(E)-2-[4-(3,4-dimethoxyphenyl)-6-pyrrolidin-1-yl-pyrimidin-2-yl]vinyl}-N,N-dimethylquinazolin-4-amine 

Relevant articles and documents

Fragment-Based Design of a Potent MAT2a Inhibitor and in Vivo Evaluation in an MTAP Null Xenograft Model

MAT2a is a methionine adenosyltransferase that synthesizes the essential metabolite S-adenosylmethionine (SAM) from methionine and ATP. Tumors bearing the co-deletion of p16 and MTAP genes have been shown to be sensitive to MAT2a inhibition, making it an attractive target for treatment of MTAP-deleted cancers. A fragment-based lead generation campaign identified weak but efficient hits binding in a known allosteric site. By use of structure-guided design and systematic SAR exploration, the hits were elaborated through a merging and growing strategy into an arylquinazolinone series of potent MAT2a inhibitors. The selected in vivo tool compound 28 reduced SAM-dependent methylation events in cells and inhibited proliferation of MTAP-null cells in vitro. In vivo studies showed that 28 was able to induce antitumor response in an MTAP knockout HCT116 xenograft model.

Antileishmanial activity of a series of N2, N 4-disubstituted quinazoline-2,4-diamines

A series of N2,N4-disubstituted quinazoline-2,4- diamines has been synthesized and tested against Leishmania donovani and L. amazonensis intracellular amastigotes. A structure-activity and structure-property relationship study was conducted in part using the Topliss operational scheme to identify new lead compounds. This study led to the identification of quinazolines with EC50 values in the single digit micromolar or high nanomolar range in addition to favorable physicochemical properties. Quinazoline 23 also displayed efficacy in a murine model of visceral leishmaniasis, reducing liver parasitemia by 37% when given by the intraperitoneal route at 15 mg kg-1 day-1 for 5 consecutive days. Their antileishmanial efficacy, ease of synthesis, and favorable physicochemical properties make the N2,N 4-disubstituted quinazoline-2,4-diamine compound series a suitable platform for future development of antileishmanial agents.

MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH

The present invention provides screening methods for identifying modifiers of chemosensory receptors and their ligands, e.g., by determining whether a test entity is suitable to interact with one or more interacting sites within the Venus flytrap domains of the chemosensory receptors as well as modifiers capable of modulating chemosensory receptors and their ligands.